Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSTRICh: Cabazitaxel vs Novel Hormonal Agents in Poor Risk mCRPC
NCT03295565Phase 3Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2017
- Primary completion
- Dec 2020
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cabazitaxel ginsenoside liposome injection in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Netherlands Cancer Institute. Started May 2017; status: completed.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03295565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03295565.